Peroxisome proliferator-activated receptor gamma polymorphisms and coronary heart disease

PPAR Research

Volumn , Issue , 2009, Pages

  Dallongeville, Jean ^a   Iribarren, Carlos ^b   Ferrires, Jean ^c   Lyon, Liisa ^b   Evans, Alun ^d   Go, Alan S ^b   Arveiler, Dominique ^e   Fortmann, Stephen P ^f   Ducimetire, Pierre ^c   Hlatky, Mark A ^f   Amouyel, Philippe ^a   Southwick, Audrey ^f   Quertermous, Thomas ^g   Meirhaeghe, Aline ^a  

^a INSTITUT PASTEUR DE LILLE   (France)

^b DIVISION OF RESEARCH   (United States)

^c INSERM   (France)

^d QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^e UNIVERSITÉ DE STRASBOURG   (France)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; AGED; ALLELE; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GENDER; GENOTYPE; HAPLOTYPE; HOMOZYGOTE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OBESITY; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 73549094482     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2009/543746     Document Type: Article

References (49)

1. Lehrke M., Lazar M. A., The many faces of PPAR Cell 2005 123 6 993 999
2. Feige J. N., Gelman L., Michalik L., Desvergne B., Wahli W., From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions Progress in Lipid Research 2006 45 2 120 159
3. Kostadinova R., Wahli W., Michalik L., PPARs in diseases: control mechanisms of inflammation Current Medicinal Chemistry 2005 12 25 2995 3009
4. Deeb S. S., Fajas L., Nemoto M., A Pro12Ala substitution in PPAR 2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity Nature Genetics 1998 20 3 284 287
5. Meirhaeghe A., Fajas L., Helbecque N., A genetic polymorphism of the peroxisome proliferator-activated receptor gene influences plasma leptin levels in obese humans Human Molecular Genetics 1998 7 3 435 440
6. Meirhaeghe A., Fajas L., Gouilleux F., A functional polymorphism in a STAT5B site of the human PPAR 3 gene promoter affects height and lipid metabolism in a French population Arteriosclerosis, Thrombosis, and Vascular Biology 2003 23 2 289 294
7. Meirhaeghe A., Tanck M. W. T., Fajas L., Study of a new PPAR 2 promoter polymorphism and haplotype analysis in a French population Molecular Genetics and Metabolism 2005 85 2 140 148
8. Meirhaeghe A., Cottel D., Amouyel P., Dallongeville J., Association between peroxisome proliferator-activated receptor haplotypes and the metabolic syndrome in French men and women Diabetes 2005 54 10 3043 3048
9. Ridker P. M., Cook N. R., Cheng S., Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction Arteriosclerosis, Thrombosis, and Vascular Biology 2003 23 5 859 863
10. Pischon T., Pai J. K., Manson J. E., Peroxisome proliferator-activated receptor- 2 P12A polymorphism and risk of coronary heart disease in US men and women Arteriosclerosis, Thrombosis, and Vascular Biology 2005 25 8 1654 1658
11. Yarnell J. W. G., The PRIME study: classical risk factors do not explain the severalfold differences in risk of coronary heart disease between France and Northern Ireland QJM 1998 91 10 667 676
12. Ducimetiere P., Ruidavets J.-B, Montaye M., Haas B., Yarnell J., Five-year incidence of angina pectoris and other forms of coronary heart disease in healthy men aged 5059 in France and Northern Ireland: the prospective epidemiological study of myocardial infarction (PRIME) study International Journal of Epidemiology 2001 30 5 1057 1062
13. Hughes G. H., Cutter G., Donahue R., Recruitment in the coronary artery disease risk development in young adults (cardia) study Controlled Clinical Trials 1987 8 4, supplement 1 68S 73S
14. Go A. S., Iribarren C., Chandra M., Statin and -blocker therapy and the initial presentation of coronary heart disease Annals of Internal Medicine 2006 144 4 229 238
15. Iribarren C., Go A. S., Husson G., Metabolic syndrome and early-onset coronary artery disease. is the whole greater than its parts? Journal of the American College of Cardiology 2006 48 9 1800 1807
16. Hlatky M. A., Ashley E., Quertermous T., Matrix metalloproteinase circulating levels, genetic polymorphisms, and susceptibility to acute myocardial infarction among patients with coronary artery disease American Heart Journal 2007 154 6 1043 1051
17. Assimes T. L., Knowles J. W., Basu A., Susceptibility locus for clinical and subclinical coronary artery disease at chromosome 9p21 in the multi-ethnic ADVANCE study Human Molecular Genetics 2008 17 15 2320 2328
18. Slatkin M., Excoffier L., Testing for linkage disequilibrium in genotypic data using the Expectation-Maximization algorithm Heredity 1996 76 4 377 383
19. Lewontin R. C., The interaction of selection and linkage. I. General considerations; heterotic models Genetics 1964 49 1 49 67
20. Tregouet D. A., Barbaux S., Escolano S., Specific haplotypes of the P-selectin gene are associated with myocardial infarction Human Molecular Genetics 2002 11 17 2015 2023
21. Tregouet D. A., Escolano S., Tiret L., Mallet A., Golmard J. L., A new algorithm for haplotype-based association analysis: the stochastic-EM algorithm Annals of Human Genetics 2004 68 2 165 177
22. Doney A. S., Fischer B., Leese G., Morris A. D., Palmer C. N. A., Cardiovascular risk in type 2 diabetes is associated with variation at the PPARG locus: a go-DARTS study Arteriosclerosis, Thrombosis, and Vascular Biology 2004 24 12 2403 2407
23. Gallicchio L., Kalesan B., Huang H. Y., Strickland P., Hoffman S. C., Helzlsouer K. J., Genetic polymorphisms of peroxisome proliferator-activated receptors and the risk of cardiovascular morbidity and mortality in a community-based cohort in washington county, Maryland PPAR Research 2008 2008 9
24. Review Manager (RevMan) [Computer program],. Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008
25. Szeto C. C., Chow K.-M., Poon P. Y.-K., Kwan B. C.-H., Li P. K.-T., Peroxisome proliferator-activated receptor-gamma gene polymorphism and risk of cardiovascular disease in patients with diabetic nephropathy American Journal of Nephrology 2008 28 5 715 722
26. Ruiz-Narvez E. A., Kraft P., Campos H., Ala12 variant of the peroxisome proliferator-activated receptor- gene (PPARG) is associated with higher polyunsaturated fat in adipose tissue and attenuates the protective effect of polyunsaturated fat intake on the risk of myocardial infarction American Journal of Clinical Nutrition 2007 86 4 1238 1242
27. Li L., Cheng L.-X., Nsenga R., He M.-A., Wu T.-C., Association between Pro 12Ala polymorphism of peroxisome proliferator-activated receptor-gamma 2 and myocardial infarction in the Chinese Han population Clinical Cardiology 2006 29 7 300 304
28. Tobin M. D., Braund P. S., Burton P. R., Genotypes and haplotypes predisposing to myocardial infarction: a multilocus case-control study European Heart Journal 2004 25 6 459 467
29. Vogel U., Segel S., Dethlefsen C., PPARgamma Pro12Ala polymorphism and risk of acute coronary syndrome in a prospective study of Danes BMC Medical Genetics 2009 10 52
30. Gallicchio L., Chang H., Christo D. K., Single nucleotide polymorphisms in inflammation-related genes and mortality in a community-based cohort in Washington County, Maryland American Journal of Epidemiology 2008 167 7 807 813
31. Zafarmand M. H., van der Schouw Y. T., Grobbee D. E., de Leeuw P. W., Bots M. L., Peroxisome proliferator-activated receptor gamma-2 P12A polymorphism and risk of acute myocardial infarction, coronary heart disease and ischemic stroke: a case-cohort study and meta-analyses Vascular Health and Risk Management 2008 4 2 427 436
32. Rhee E. J., Kwon C. H., Lee W. Y., No association of Pro12Ala polymorphism of PPAR- gene with coronary artery disease in Korean subjects Circulation Journal 2007 71 3 338 342
33. Bluher M., Klemm T., Gerike T., Krankenberg H., Schuler G., Paschke R., Lack of association between peroxisome proliferator-activated receptor- -2 gene variants and the occurrence of coronary heart disease in patients with diabetes mellitus European Journal of Endocrinology 2002 146 4 545 551
34. Iwata E., Yamamoto I., Motomura T., The association of Pro12Ala polymorphism in PPAR 2 with lower carotid artery IMT in Japanese Diabetes Research and Clinical Practice 2003 62 1 55 59
35. Temelkova-Kurktschiev T., Hanefeld M., Chinetti G., Ala12Ala genotype of the peroxisome proliferator-activated receptor 2 protects against atherosclerosis Journal of Clinical Endocrinology and Metabolism 2004 89 9 4238 4242
36. Al-Shali K. Z., House A. A., Hanley A. J. G., Genetic variation in PPARG encoding peroxisome proliferator-activated receptor associated with carotid atherosclerosis Stroke 2004 35 9 2036 2040
37. McPherson R., Pertsemlidis A., Kavaslar N., A common allele on chromosome 9 associated with coronary heart disease Science 2007 316 5830 1488 1491
38. Helgadottir A., Thorleifsson G., Manolescu A., A common variant on chromosome 9p21 affects the risk of myocardial infarction Science 2007 316 5830 1491 1493 (Pubitemid 46906618)
39. Samani N. J., Erdmann J., Hall A. S., Genomewide association analysis of coronary artery disease The New England Journal of Medicine 2007 357 5 443 453 (Pubitemid 47204873)
40. Burton P. R., Clayton D. G., Cardon L. R., Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls Nature 2007 447 7145 661 678
41. Erdmann J., Grosshennig A., Braund P. S., New susceptibility locus for coronary artery disease on chromosome 3q22.3 Nature Genetics 2009 41 3 280 282
42. Tregouet D. A., Konig I. R., Erdmann J., Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease Nature Genetics 2009 41 3 283 285
43. Horiki M., Ikegami H., Fujisawa T., Association of Pro12Ala polymorphism of PPARgamma gene with insulin resistance and related diseases Diabetes Research and Clinical Practice 2004 66 supplement 1 S63 S67
44. Rodrguez-Esparragn F. J., Rodrguez-Prez J. C., Macas-Reyes A., Alamo-Santana F., Peroxisome proliferator-activated receptor-gamma2-Pro12Ala and endothelial nitric oxide synthase-4a/b gene polymorphisms are associated with essential hypertension Journal of Hypertension 2003 21 9 1649 1655
45. stgren C. J., Lindblad U., Melander O., Melander A., Groop L., Rstam L., Peroxisome proliferator-activated receptor- Pro12Ala polymorphism and the association with blood pressure in type 2 diabetes: skaraborg hypertension and diabetes project Journal of Hypertension 2003 21 9 1657 1662
46. Hasstedt S. J., Ren Q.-F., Teng K., Elbein S. C., Effect of the peroxisome proliferator-activated receptor- 2 Pro12Ala variant on obesity, glucose homeostasis, and blood pressure in members of familial type 2 diabetic kindreds Journal of Clinical Endocrinology and Metabolism 2001 86 2 536 541
47. Douglas J. A., Erdos M. R., Watanabe R. M., The peroxisome poliferatoractivated receptor- 2 Pro 12Ala variant: association with type 2 diabetes and trait differences Diabetes 2001 50 4 886 890
48. Mori Y., Kim-Motoyama H., Katakura T., Effect of the Pro12Ala variant of the human peroxisome proliferator-activated receptor 2 gene on adiposity, fat distribution, and insulin sensitivity in Japanese men Biochemical and Biophysical Research Communications 1998 251 1 195 198
49. Gouni-Berthold I., Giannakidou E., Mller-Wieland D., Peroxisome proliferator-activated receptor- 2 Pro12Ala and endothelial nitric oxide synthase-4a/b gene polymorphisms are not associated with hypertension in diabetes mellitus type 2 Journal of Hypertension 2005 23 2 301 308